7,386 Shares in Danaher Corporation $DHR Purchased by Clearline Capital LP

Key Points

• Clearline Capital LP has acquired 7,386 shares of Danaher Corporation, valued at approximately $1.5 million, marking a notable entry into the stock during the first quarter.
• Institutional investors hold a significant 79.05% of Danaher's stock, with several firms, including MGO One Seven LLC and Horizon Financial Services LLC, substantially increasing their positions in the company.
• Analysts have varied expectations for Danaher, with a consensus price target of $246.35 and several firms reaffirming buy ratings despite some lowering their price targets.

Clearline Capital LP acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 7,386 shares of the conglomerate's stock, valued at approximately $1,514,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in DHR. Nuveen LLC acquired a new position in shares of Danaher during the 1st quarter worth about $833,941,000. GAMMA Investing LLC grew its position in shares of Danaher by 24,958.2% during the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after buying an additional 1,863,381 shares during the period. Two Sigma Advisers LP grew its position in shares of Danaher by 4,248.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after buying an additional 1,601,800 shares during the period. Invesco Ltd. grew its position in shares of Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after buying an additional 1,450,703 shares during the period. Finally, Point72 Asset Management L.P. grew its position in shares of Danaher by 460.6% during the 4th quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after buying an additional 1,107,998 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Evercore ISI decreased their target price on Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Royal Bank Of Canada set a $241.00 target price on Danaher in a research note on Tuesday, September 2nd. Barclays reaffirmed an "overweight" rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target for the company in a report on Friday, July 11th. Finally, UBS Group reduced their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $246.35.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 11.10% of the stock is currently owned by corporate insiders.

Danaher Stock Up 1.4%

NYSE:DHR traded up $2.64 during trading hours on Thursday, reaching $195.23. 3,425,999 shares of the stock were exchanged, compared to its average volume of 4,141,844. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. The firm has a 50 day moving average of $201.62 and a 200 day moving average of $199.15. The stock has a market cap of $139.79 billion, a PE ratio of 41.54, a PEG ratio of 2.71 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company's quarterly revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts expect that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's payout ratio is 27.23%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.